Page last updated: 2024-11-06

homoeriodictyol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Homoeriodictyol is a flavonoid found in various plants, including honeybush (Cyclopia intermedia) and the leaves of the lemon balm (Melissa officinalis). Its potential health benefits are being studied. Research suggests it may have antioxidant, anti-inflammatory, and neuroprotective properties. It is also being investigated for its potential to help with conditions like Alzheimer's disease and cancer. Homoeriodictyol is synthesized naturally by plants and is also being studied for its potential therapeutic applications.'

homoeriodictyol: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

homoeriodictyol : A trihydroxyflavanone that consists of 3'-methoxyflavanone in which the three hydroxy substituents are located at positions 4', 5, and 7. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID73635
CHEMBL ID490170
CHEBI ID74960
SCHEMBL ID39497
MeSH IDM0488569

Synonyms (38)

Synonym
5,7,4'-trihydroxy-3'-methoxyflavanone
unii-ehe7h3705c
ehe7h3705c ,
eriodictyonone
(s)-2,3-dihydro-5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4-benzopyrone
einecs 207-173-3
C09756
eriodictyol 3'-methyl ether
446-71-9
homoeriodictyol
4h-1-benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-, (2s)-
(2s)-5,7-dihydroxy-2-(4-hydroxy-3-methoxy-phenyl)chroman-4-one
NCGC00163565-01
(-)-homoeriodictyol
LMPK12140449
(2s)-5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-2,3-dihydrochromen-4-one
CHEMBL490170 ,
chebi:74960 ,
5,7,4''-trihydroxy-3''-methoxyflavanone
bdbm50325672
(2s)-5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-2,3-dihydro-4h-chromen-4-one
(s)-homoeriodictyol
homoeriodictyol [mi]
CCG-208391
SCHEMBL39497
mfcd00270390
Q-100585
(.+/-.)-5,7,4'-trihydroxy-3'-methoxyflavanone
FTODBIPDTXRIGS-ZDUSSCGKSA-N
DTXSID30196243
Q3139901
(s)-5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)chroman-4-one
MS-24355
4h-1-benzopyran-4-one,2,3-dihydro-5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-, (2s)-
3'-methoxy-5,7,4'-trihydroxyflavanone
CS-0140307
HY-N8210
AKOS040760449

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"The chirality of flavonoids has been overlooked in the majority of pharmacokinetic studies of homoeriodictyol, isosakuranetin, and taxifolin."( Stereospecific pharmacokinetics of racemic homoeriodictyol, isosakuranetin, and taxifolin in rats and their disposition in fruit.
Andrews, PK; Davies, NM; Ohgami, Y; Remsberg, CM; Takemoto, JK; Vega-Villa, KR; Yáñez, JA, 2011
)
0.85

Dosage Studied

ExcerptRelevanceReference
" For caffeine and amarogentin, dose-response studies were performed; the masking activity toward bitter taste for both compounds reached a plateau at higher concentrations of 1-Na."( Evaluation of bitter masking flavanones from Herba Santa (Eriodictyon californicum (H. and A.) Torr., Hydrophyllaceae).
Bertram, HJ; Gatfield, IL; Krammer, G; Ley, JP; Reinders, G, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
flavouring agentA food additive that is used to added improve the taste or odour of a food.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
monomethoxyflavanoneAny methoxyflavanone that is flavanone substituted by a methoxy group.
trihydroxyflavanoneA hydroxyflavanone carrying three hydroxy substituents.
3'-methoxyflavanonesAny methoxyflavanone having a methoxy substituent located at position 3'.
4'-hydroxyflavanonesAny hydroxyflavanone having a hydroxy substituent located at position 4'.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Flavonoid Biosynthesis1150

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency17.78285.623417.292931.6228AID485281
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 1A1Homo sapiens (human)IC50 (µMol)11.55450.00791.24789.9000AID311073; AID502474
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)20.88400.00011.774010.0000AID311074; AID502473
Cytochrome P450 1B1Homo sapiens (human)IC50 (µMol)0.97800.00130.86969.9000AID311072; AID502475
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (104)

Processvia Protein(s)Taxonomy
cellular response to organic cyclic compoundCytochrome P450 1A1Homo sapiens (human)
response to hypoxiaCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 1A1Homo sapiens (human)
lipid hydroxylationCytochrome P450 1A1Homo sapiens (human)
fatty acid metabolic processCytochrome P450 1A1Homo sapiens (human)
steroid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A1Homo sapiens (human)
steroid metabolic processCytochrome P450 1A1Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A1Homo sapiens (human)
amine metabolic processCytochrome P450 1A1Homo sapiens (human)
response to nematodeCytochrome P450 1A1Homo sapiens (human)
response to herbicideCytochrome P450 1A1Homo sapiens (human)
ethylene metabolic processCytochrome P450 1A1Homo sapiens (human)
coumarin metabolic processCytochrome P450 1A1Homo sapiens (human)
flavonoid metabolic processCytochrome P450 1A1Homo sapiens (human)
response to iron(III) ionCytochrome P450 1A1Homo sapiens (human)
insecticide metabolic processCytochrome P450 1A1Homo sapiens (human)
dibenzo-p-dioxin catabolic processCytochrome P450 1A1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A1Homo sapiens (human)
response to foodCytochrome P450 1A1Homo sapiens (human)
response to lipopolysaccharideCytochrome P450 1A1Homo sapiens (human)
response to vitamin ACytochrome P450 1A1Homo sapiens (human)
response to immobilization stressCytochrome P450 1A1Homo sapiens (human)
vitamin D metabolic processCytochrome P450 1A1Homo sapiens (human)
retinol metabolic processCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
9-cis-retinoic acid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
camera-type eye developmentCytochrome P450 1A1Homo sapiens (human)
nitric oxide metabolic processCytochrome P450 1A1Homo sapiens (human)
response to arsenic-containing substanceCytochrome P450 1A1Homo sapiens (human)
digestive tract developmentCytochrome P450 1A1Homo sapiens (human)
tissue remodelingCytochrome P450 1A1Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A1Homo sapiens (human)
response to hyperoxiaCytochrome P450 1A1Homo sapiens (human)
maternal process involved in parturitionCytochrome P450 1A1Homo sapiens (human)
hepatocyte differentiationCytochrome P450 1A1Homo sapiens (human)
cellular response to copper ionCytochrome P450 1A1Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A1Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleCytochrome P450 1A1Homo sapiens (human)
response to 3-methylcholanthreneCytochrome P450 1A1Homo sapiens (human)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
cellular response to organic cyclic compoundCytochrome P450 1B1Homo sapiens (human)
angiogenesisCytochrome P450 1B1Homo sapiens (human)
trabecular meshwork developmentCytochrome P450 1B1Homo sapiens (human)
DNA modificationCytochrome P450 1B1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1B1Homo sapiens (human)
nitric oxide biosynthetic processCytochrome P450 1B1Homo sapiens (human)
cell adhesionCytochrome P450 1B1Homo sapiens (human)
response to nutrientCytochrome P450 1B1Homo sapiens (human)
steroid metabolic processCytochrome P450 1B1Homo sapiens (human)
estrogen metabolic processCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell population proliferationCytochrome P450 1B1Homo sapiens (human)
male gonad developmentCytochrome P450 1B1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressCytochrome P450 1B1Homo sapiens (human)
toxin metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionCytochrome P450 1B1Homo sapiens (human)
positive regulation of smooth muscle cell migrationCytochrome P450 1B1Homo sapiens (human)
sterol metabolic processCytochrome P450 1B1Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 1B1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1B1Homo sapiens (human)
collagen fibril organizationCytochrome P450 1B1Homo sapiens (human)
adrenal gland developmentCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell migrationCytochrome P450 1B1Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityCytochrome P450 1B1Homo sapiens (human)
response to follicle-stimulating hormoneCytochrome P450 1B1Homo sapiens (human)
response to estradiolCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell adhesion mediated by integrinCytochrome P450 1B1Homo sapiens (human)
benzene-containing compound metabolic processCytochrome P450 1B1Homo sapiens (human)
retinol metabolic processCytochrome P450 1B1Homo sapiens (human)
retinal metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of apoptotic processCytochrome P450 1B1Homo sapiens (human)
blood vessel endothelial cell migrationCytochrome P450 1B1Homo sapiens (human)
endothelial cell migrationCytochrome P450 1B1Homo sapiens (human)
estrous cycleCytochrome P450 1B1Homo sapiens (human)
positive regulation of translationCytochrome P450 1B1Homo sapiens (human)
positive regulation of angiogenesisCytochrome P450 1B1Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATCytochrome P450 1B1Homo sapiens (human)
membrane lipid catabolic processCytochrome P450 1B1Homo sapiens (human)
response to arsenic-containing substanceCytochrome P450 1B1Homo sapiens (human)
blood vessel morphogenesisCytochrome P450 1B1Homo sapiens (human)
retinal blood vessel morphogenesisCytochrome P450 1B1Homo sapiens (human)
ganglion developmentCytochrome P450 1B1Homo sapiens (human)
cellular response to hydrogen peroxideCytochrome P450 1B1Homo sapiens (human)
cellular response to cAMPCytochrome P450 1B1Homo sapiens (human)
cellular response to tumor necrosis factorCytochrome P450 1B1Homo sapiens (human)
cellular response to luteinizing hormone stimulusCytochrome P450 1B1Homo sapiens (human)
cellular response to cortisol stimulusCytochrome P450 1B1Homo sapiens (human)
cellular response to progesterone stimulusCytochrome P450 1B1Homo sapiens (human)
response to dexamethasoneCytochrome P450 1B1Homo sapiens (human)
endothelial cell-cell adhesionCytochrome P450 1B1Homo sapiens (human)
response to indole-3-methanolCytochrome P450 1B1Homo sapiens (human)
cellular response to toxic substanceCytochrome P450 1B1Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1B1Homo sapiens (human)
response to 3-methylcholanthreneCytochrome P450 1B1Homo sapiens (human)
regulation of reactive oxygen species metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of DNA biosynthetic processCytochrome P450 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (24)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
iron ion bindingCytochrome P450 1A1Homo sapiens (human)
protein bindingCytochrome P450 1A1Homo sapiens (human)
arachidonic acid monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A1Homo sapiens (human)
oxidoreductase activity, acting on diphenols and related substances as donorsCytochrome P450 1A1Homo sapiens (human)
flavonoid 3'-monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
oxygen bindingCytochrome P450 1A1Homo sapiens (human)
enzyme bindingCytochrome P450 1A1Homo sapiens (human)
heme bindingCytochrome P450 1A1Homo sapiens (human)
Hsp70 protein bindingCytochrome P450 1A1Homo sapiens (human)
demethylase activityCytochrome P450 1A1Homo sapiens (human)
Hsp90 protein bindingCytochrome P450 1A1Homo sapiens (human)
aromatase activityCytochrome P450 1A1Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid omega-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
monooxygenase activityCytochrome P450 1B1Homo sapiens (human)
iron ion bindingCytochrome P450 1B1Homo sapiens (human)
protein bindingCytochrome P450 1B1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1B1Homo sapiens (human)
heme bindingCytochrome P450 1B1Homo sapiens (human)
aromatase activityCytochrome P450 1B1Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1B1Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1B1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygenCytochrome P450 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
mitochondrial inner membraneCytochrome P450 1A1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
mitochondrionCytochrome P450 1B1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1B1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (32)

Assay IDTitleYearJournalArticle
AID1264955Cytotoxicity against human MSC assessed as cell viability at 10 uM treated for 3 days measured on day 4 by alamar blue assay (Rvb = 97 to 100%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID400607Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression at 10 uM after 18 hrs measured as microunits of tissue factor/10'5 cells1996Journal of natural products, Mar, Volume: 59, Issue:3
Ability of different flavonoids to inhibit the procoagulant activity of adherent human monocytes.
AID1264953Cytotoxicity against human MSC assessed as cell viability at 1 uM treated for 3 days measured on day 4 by alamar blue assay (Rvb = 97 to 100%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1129937Retention time of the compound by PDA chromatography2014Journal of natural products, Apr-25, Volume: 77, Issue:4
UPLC-MS-ELSD-PDA as a powerful dereplication tool to facilitate compound identification from small-molecule natural product libraries.
AID1264947Induction of osteogenic differentiation in human MSC assessed as increase in ALP activity at 10 uM using p-NPP as substrate after 9 days by colorimetric method relative to control2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1264957Cytotoxicity against human MSC assessed as cell viability at 5 uM treated for 6 days measured on day 7 by alamar blue assay (Rvb = 96 to 101%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID600288Vasorelaxant activity in rat aortic ring assessed as inhibition of phenylephrine-induced contraction2009Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12
Synthesis, biological evaluation of prenylflavonoids as vasorelaxant and neuroprotective agents.
AID600289Neuroprotective activity against oxygen-glucose deprivation-induced cell injury in rat PC12 cells assessed as cell viability at 1 uM2009Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12
Synthesis, biological evaluation of prenylflavonoids as vasorelaxant and neuroprotective agents.
AID600292Vasorelaxant activity in rat aortic ring assessed as inhibition of phenylephrine-induced contraction relative to control2009Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12
Synthesis, biological evaluation of prenylflavonoids as vasorelaxant and neuroprotective agents.
AID1264956Cytotoxicity against human MSC assessed as cell viability at 1 uM treated for 6 days measured on day 7 by alamar blue assay (Rvb = 96 to 101%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1264952Cytotoxicity against human MSC assessed as cell viability at 10 uM measured on day 1 by alamar blue assay (Rvb = 97 to 101%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1264951Cytotoxicity against human MSC assessed as cell viability at 5 uM measured on day 1 by alamar blue assay (Rvb = 97 to 101%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1264945Induction of osteogenic differentiation in human MSC assessed as increase in ALP activity at 1 uM using p-NPP as substrate after 9 days by colorimetric method relative to control2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID311072Inhibition of CYP1B12007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1264946Induction of osteogenic differentiation in human MSC assessed as increase in ALP activity at 5 uM using p-NPP as substrate after 9 days by colorimetric method relative to control2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID1264954Cytotoxicity against human MSC assessed as cell viability at 5 uM treated for 3 days measured on day 4 by alamar blue assay (Rvb = 97 to 100%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID311074Inhibition of CYP1A22007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development.
AID1129936Retention time of the compound by ELSD chromatography2014Journal of natural products, Apr-25, Volume: 77, Issue:4
UPLC-MS-ELSD-PDA as a powerful dereplication tool to facilitate compound identification from small-molecule natural product libraries.
AID1264958Cytotoxicity against human MSC assessed as cell viability at 10 uM treated for 6 days measured on day 7 by alamar blue assay (Rvb = 96 to 101%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID311073Inhibition of CYP1A12007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development.
AID1452995Inhibition of CYP1B1 in human liver microsomes using ethoxyresorufin as substrate preincubated for 2 mins followed by NADPH addition measured after 5 mins by fluorescence assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Inhibitors of cytochrome P450 (CYP) 1B1.
AID1400536Activation of Nrf2 in mouse Heap1c1c7 cells assessed as induction of NAD(P)H:quinone reductase activity at 50 uM relative to control2018Bioorganic & medicinal chemistry, 10-01, Volume: 26, Issue:18
Discovery of natural flavonoids as activators of Nrf2-mediated defense system: Structure-activity relationship and inhibition of intracellular oxidative insults.
AID502474Inhibition of human CYP1A1 by EROD assay2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Selective inhibition of methoxyflavonoids on human CYP1B1 activity.
AID1264950Cytotoxicity against human MSC assessed as cell viability at 1 uM measured on day 1 by alamar blue assay (Rvb = 97 to 101%)2015Journal of natural products, Nov-25, Volume: 78, Issue:11
Defining Key Structural Determinants for the Pro-osteogenic Activity of Flavonoids.
AID502473Inhibition of human CYP1A2 by EROD assay2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Selective inhibition of methoxyflavonoids on human CYP1B1 activity.
AID353303Increase in EGR1 mRNA expression in human HEK293 cells at 20 ug/mL after 6 to 12 hrs by dual-glo luciferase assay relative to control2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Relationships between the structures of flavanone derivatives and their effects in enhancing early growth response-1 gene expression.
AID1452996Inhibition of CYP1A1 in human liver microsomes using ethoxyresorufin as substrate preincubated for 2 mins followed by NADPH addition measured after 5 mins by fluorescence assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Inhibitors of cytochrome P450 (CYP) 1B1.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID334444Chemopreventive activity in Syrian hamster embryo cells assessed as inhibition of metabolism of [3H]benzo(a)pyrene to water-soluble metabolites after 24 hrs at 20 ug/ml relative to control1992Journal of natural products, Mar, Volume: 55, Issue:3
Isolation of potential cancer chemopreventive agents from Eriodictyon californicum.
AID502475Inhibition of human CYP1B1 by EROD assay2010Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17
Selective inhibition of methoxyflavonoids on human CYP1B1 activity.
AID1452997Inhibition of CYP1A2 in human liver microsomes using ethoxyresorufin as substrate preincubated for 2 mins followed by NADPH addition measured after 5 mins by fluorescence assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Inhibitors of cytochrome P450 (CYP) 1B1.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (6.06)18.2507
2000's12 (36.36)29.6817
2010's17 (51.52)24.3611
2020's2 (6.06)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.48

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.48 (24.57)
Research Supply Index3.56 (2.92)
Research Growth Index5.24 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.48)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (3.03%)5.53%
Reviews2 (6.06%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other30 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]